Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/breast-cancer-clinical-practice-recommendations-from-saint-paul-de-Ly1Y5GUKE4
References (77)
-
(2004)
A multicenter study with trastuzumab and vinorelbine as first- and second-line treatment in patients (pats) with HER2 positive Metastatic Breast Cancer (MBC) -
DJ Slamon, B Leyland-Jones, S Shak (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med, 344
-
W. Carney, R. Neumann, A. Lipton, K. Leitzel, Suhail Ali, C. Price (2004)
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.Clinical breast cancer, 5 2
-
M. Bonaca, Deepak M.P.H., Marc M.P.H., P. Steg, M. Storey, Eva M.D., Giulia Ph.D., Sameer M.D., M. Fish, Ph.D Im, Ph.Lic Bengtsson, T. Ophuis, Ph.D Budaj, Pierre Ph.D., Mikhail M.D., Christian M.D., Shinya M.D., M. Spinar, José Nicolau, Robert Ph.D., Sabina Ph.D., M. Wiviott, Peter M.D., Eugene Ph.D., M. Sabatine (1977)
THE NEW ENGLAND JOURNAL OF MEDICINEThe Lancet, 309
-
Thomas Suter, N. Cook-Bruns, C. Barton (2004)
Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer.Breast, 13 3
-
N. Diaz (2001)
Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.Cancer control : journal of the Moffitt Cancer Center, 8 5
-
(2004)
Comparison of chromogenic in situ hybridization (CISH) with FISH and IHC for the assessment of HER2 status and prediction of response to therapy: analysis from a study of trastuzumab monotherapy -
N. Robert, B. Leyland-Jones, L. Asmar, R. Belt, D. Ilegbodu, D. Loesch, R. Raju, M. Cobleigh, K. Albain, D. Slamom (2004)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer: An update including survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
S Paik, J Bryant, E Tan-Chiu (2002)
Real-world performance of HER2 testing National Surgical Adjuvant Breast and Bowel Project ExperienceJ Natl Cancer Inst, 94
-
M De Wit, N Harbeck, C Thomssen (2004)
Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC). 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)J Clin Oncol, 22
-
M. Pegram, T. Pieńkowski, D. Northfelt, W. Eiermann, Ravi Patel, P. Fumoleau, E. Quan, J. Crown, D. Toppmeyer, M. Smylie, A. Riva, S. Blitz, M. Press, D. Reese, M. Lindsay, D. Slamon (2004)
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.Journal of the National Cancer Institute, 96 10
-
R. Nagle, Tubbs Rr, P. Roche, E. Hsi, M. Linden, A. Ormsby, N. Pettigrew, R. Rickert, J. Said, I. Bayer-Garner, L. Cooley, A. Brothman, D. Persons, G. Vance, J. Mascarello, K. Rao, M. Herrmann, G. Dewald, Jonathan Park (2002)
Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing.Archives of pathology & laboratory medicine, 126 7
-
(2003)
Preliminary clinical results of a randomized phase IIb study of weekly paclitaxel (PCT) trastuzumab (T) as first-line therapy of patients (pts) with HER2/neu positive metastatic breast cancer -
T. Jacobs, A. Gown, H. Yaziji, Melissa Barnes, S. Schnitt (1999)
Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 7
-
K. Gelmon, J. Mackey, S. Verma, S. Gertler, Nicholas Bangemann, P. Klimo, A. Schneeweiss, K. Bremer, D. Soulières, K. Tonkin, R. Bell, B. Heinrich, D. Grenier, R. Dias (2004)
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.Clinical breast cancer, 5 1
-
R. Zarbo, M. Hammond (2003)
Conference summary, Strategic Science symposium. Her-2/neu testing of breast cancer patients in clinical practice.Archives of pathology & laboratory medicine, 127 5
-
M. Ellis, A. Coop, Baljit Singh, L. Mauriac, Antonio Llombert-Cussac, F. Jänicke, W. Miller, D. Evans, M. Dugan, C. Brady, E. Quebe‐Fehling, M. Borgs (2001)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 18
-
F. Penault-Llorca, A. Balaton, J. Sabourin, V. Doussal (2002)
[Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines].Annales de pathologie, 22 2
-
A. Seidman (2006)
Effect of Doxorubicin Plus Cyclophosphamide on Left Ventricular Ejection Fraction in Patients With Breast Cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialBreast Diseases: A Year Book Quarterly, 16
-
S. Placido, M. Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, G. Pettinato, G. Petrella, A. Bianco (2003)
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 9 3
-
G. Harris, H. Denley, S. Pinder, Andrew Lee, I. Ellis, C. Elston, A. Evans (2003)
Correlation of Histologic Prognostic Factors in Core Biopsies and Therapeutic Excisions of Invasive Breast CarcinomaThe American Journal of Surgical Pathology, 27
-
M. Clarke, R. Collins, C. Davies, J. Godwin, R. Gray, R. Peto (1998)
Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 352
-
M. Dowsett, R. Stein, R. Coombes (1992)
Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patientsThe Journal of Steroid Biochemistry and Molecular Biology, 43
-
(1997)
Serum levels of c-erbB2 in patients with malignant and non malignant diseases -
NJ Robert, B Leyland-Jones, L Asmar (2004)
Slamom. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer: An update including survival. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)J Clin Oncol (Suppl.), 22
-
G. Fountzilas, E. Razis, D. Tsavdaridis, M. Karina, S. Labropoulos, C. Christodoulou, D. Mavroudis, H. Gogas, V. Georgoulias, D. Skarlos (2003)
Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.Clinical breast cancer, 4 2
-
M. Bilous, M. Dowsett, W. Hanna, J. Isola, A. Lebeau, A. Moreno, F. Penault-Llorca, J. Rüschoff, G. Tomasic, M. Vijver (2003)
Current Perspectives on HER2 Testing: A Review of National Testing GuidelinesModern Pathology, 16
-
W. Hanna, H. Kahn, Margaret Pienkowska, J. Blondal, A. Seth, Alexander Marks (2001)
Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic SettingModern Pathology, 14
-
G. Fountzilas, C. Christodoulou, D. Tsavdaridis, A. Kalogera-Fountzila, G. Aravantinos, E. Razis, H. Kalofonos, P. Papakostas, M. Karina, H. Gogas, D. Skarlos (2004)
Paclitaxel and Gemcitabine, As First-Line Chemotherapy, Combined with Trastuzumab in Patients with Advanced Breast Cancer: A Phase II Study Conducted by the Hellenic Cooperative Oncology Group (HeCOG)Cancer Investigation, 22
-
H. Burstein, I. Kuter, S. Campos, R. Gelman, Laura Tribou, L. Parker, J. Manola, J. Younger, U. Matulonis, C. Bunnell, A. Partridge, P. Richardson, K. Clarke, Lawrence Shulman, E. Winer (2001)
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
-
J. Ingle (2005)
Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 2 Pt 2
-
P. Roche, V. Suman, R. Jenkins, N. Davidson, S. Martino, P. Kaufman, F. Addo, B. Murphy, J. Ingle, E. Perez (2002)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.Journal of the National Cancer Institute, 94 11
-
M. Cobleigh, C. Vogel, D. Tripathy, N. Robert, S. Scholl, L. Fehrenbacher, J. Wolter, V. Paton, S. Shak, G. Lieberman, D. Slamon (1999)
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 9
-
D. Tripathy, D. Slamon, M. Cobleigh, A. Arnold, M. Saleh, J. Mortimer, M. Murphy, S. Stewart (2004)
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 6
-
MD Pegram, T Pienkowski, DW Northfelt (2004)
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancerJ Natl Cancer Inst, 96
-
R. Love, N. Duc, T. Havighurst, S. Mohsin, Qian Zhang, D. DeMets, D. Allred (2003)
Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 3
-
EA Perez, VJ Suman, NE Davidson (2004)
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialJ Clin Oncol, 22
-
First - line trastuzumab ( Herceptin ) plus docetaxel versus docetaxel alone in women with HER 2 - positive metastatic breast cancer ( MBC ) : Results from a randomized phase II trial ( M 77001 ) -
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.The New England journal of medicine, 353 16
-
A. Lipton, S. Ali, K. Leitzel, L. Demers, H. Harvey, H. Chaudri-Ross, C. Brady, P. Wyld, W. Carney (2003)
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 10
-
R. Molina, J. Jo, X. Filella, J. Bruix, A. Castells, M. Hague, A. Ballesta (1997)
Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 18 3
-
S Rodenhuis, M Bontenbal, LV Beex (2003)
Netherlands Working Party on Autologous Transplantation in Solid Tumors. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancerN Engl J Med, 349
-
J. Isola, M. Tanner (2004)
Chromogenic in situ hybridization in tumor pathology.Methods in molecular medicine, 97
-
S. Rodenhuis, M. Bontenbal, L. Beex, J. Wagstaff, D. Richel, M. Nooij, E. Voest, P. Hupperets, H. Tinteren, H. Peterse, E. Tenvergert, E. Vries (2003)
High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.The New England journal of medicine, 349 1
-
G. Fountzilas, D. Tsavdaridis, A. Kalogera-Fountzila, C. Christodoulou, E. Timotheadou, Kalofonos Ch, P. Kosmidis, A. Adamou, P. Papakostas, H. Gogas, G. Stathopoulos, E. Razis, D. Bafaloukos, D. Skarlos (2001)
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 12 11
-
(2004)
Results of a phase II trial of Herceptin plus Xeloda in patients with previously untreated HER2-positive metastatic breast cancer -
D. Lftner, C. Cheli, K. Mickelson, E. Sampson, K. Possinger (2004)
ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.The International journal of biological markers, 19 3
-
Ian Ellis, J. Bartlett, Mitchell Dowsett, S. Humphreys, Bharat Jasani, Keith Miller, Sarah Pinder, Anthony Rhodes, Rosemary Walker (2004)
Best Practice No 176Journal of Clinical Pathology, 57
-
C. Vogel, M. Cobleigh, D. Tripathy, J. Gutheil, L. Harris, L. Fehrenbacher, D. Slamon, M. Murphy, W. Novotny, M. Burchmore, S. Shak, S. Stewart, M. Press (2023)
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 41
-
J. Baselga, Xavier Carbonell, N. Castañeda-Soto, M. Clemens, Michael Green, V. Harvey, S. Morales, C. Barton, P. Ghahramani (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 10
-
(2004)
Statut actuel des tests HER2 -
T. Jacobs, A. Gown, H. Yaziji, Melissa Barnes, Stuart Schnitt (2000)
HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement.American journal of clinical pathology, 113 2
-
A. Seidman, M. Fornier, F. Esteva, L. Tan, Stamatina Kaptain, A. Bach, K. Panageas, C. Arroyo, V. Valero, V. Currie, T. Gilewski, M. Theodoulou, M. Moynahan, M. Moasser, N. Sklarin, M. Dickler, G. D’Andrea, M. Cristofanilli, E. Rivera, G. Hortobagyi, L. Norton, C. Hudis (2001)
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 10
-
R. Zarbo, B. Jones, R. Friedberg, P. Valenstein, S. Renner, R. Schifman, M. Walsh, P. Howanitz (2002)
Q-tracks: a College of American Pathologists program of continuous laboratory monitoring and longitudinal tracking.Archives of pathology & laboratory medicine, 126 9
-
M. Wit, N. Harbeck, C. Thomssen, K. Becker, A. Psonka, R. Hoffmann, C. Villena, M. Schutte, D. Hossfeld (2004)
Interim results of a prospective, open-label, multicentre phase II trial of the efficacy and safety of vinorelbine (N) and trastuzumab (H) in patients with HER2-positive metastatic breast cancer (MBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 14_suppl
-
J. Extra, F. Cognetti, S. Chan, D. Maraninchi, R. Snyder, A. Lluch, M. Tubiana‐Hulin, D. Grimes, K. Mayne, M. Marty (2003)
672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancerEjc Supplements, 1
-
F. Esteva, V. Valero, D. Booser, L. Guerra, J. Murray, L. Pusztai, M. Cristofanilli, B. Arun, B. Esmaeli, H. Fritsche, N. Sneige, T. Smith, G. Hortobagyi (2002)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 7
-
(2002)
Clinical Laboratory Assays for Her2/neu amplification and overexpressionArch Pathol Lab Med, 126
-
IO Ellis, J Bartlett, M Dowsett (2004)
Best Practice No 176: Updated recommendations for HER2 testing in the UKJ Clin Pathol, 57
-
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
-
C. Tse, D. Brault, J. Gligorov, M. Antoine, R. Neumann, J. Lotz, J. Capeau (2005)
Evaluation of the quantitative analytical methods real-time PCR for HER-2 gene quantification and ELISA of serum HER-2 protein and comparison with fluorescence in situ hybridization and immunohistochemistry for determining HER-2 status in breast cancer patients.Clinical chemistry, 51 7
-
Sylvie Ménard, P. Casalini, M. Campiglio, S. Pupa, R. Agresti, E. Tagliabue (2001)
HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 12 Suppl 1
-
Y. Denoux, L. Arnould, M. Fiche, B. Lannes, J. Couturier, A. Vincent-Salomon, F. Penault-llorca, M. Antoine, A. Balaton, M. Baranzelli, Becette, J. Bellocq, F. Bibeau, F. Ettore, Fridman, J. Gnassia, J. Jacquemier, G. Macgrogan, M. Mathieu, C. Migeon, C. Rigaud, P. Roger, B. Sigal-Zafrani, J. Simony-Lafontaine, M. Trassard, I. Treilleux, Verriele, J. Voigt (2003)
Recherche de l'amplification du gène HER2: la CISH est-elle une alternative à la technique FISH?Annales De Pathologie, 23
-
C. Osborne, J. Shou, S. Massarweh, R. Schiff (2005)
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 2 Pt 2
-
C. Hauser-kronberger, N. Dandachi (2004)
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancerJournal of Molecular Histology, 35
-
A. Vincent-Salomon, G. MacGrogan, J. Couturier, Laurent Arnould, Yves Denoux, Maryse Fiche, J. Jacquemier, M. Mathieu, Frédérique Penault-Llorca, C. Rigaud, P. Roger, Isabelle Treilleux, M. Vilain, S. Mathoulin-Pélissier, V. Doussal (2003)
Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS * StudyHistopathology, 42
-
J. Carlsson, H. Nordgren, J. Sjöström, K. Wester, K. Villman, N. Bengtsson, B. Østenstad, Hans Lundqvist, C. Blomqvist (2004)
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature reviewBritish Journal of Cancer, 90
-
(1999)
Specificity of HerceptestTM in determining HER/neu Status of breast cancers using FDA-approved scoring system -
G Fountzilas, C Christodoulou, D Tsavdaridis (2004)
Related Articles, Links. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)Cancer Invest, 22
-
Martin Tallman, R. Gray, Nicholas Robert, C. LeMaistre, C. Osborne, William Vaughan, W. Gradishar, T. Pisansky, J. Fetting, E. Paietta, Hillard Lazarus (2003)
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.The New England journal of medicine, 349 1
-
(2002)
Évaluation immunohistochimique du statut HER2 dans les carcinomes mammaires infiltrants : mise au point du protocole technique et de la lecture des résultats - Recommandations -
S. Paik, J. Bryant, E. Tan-chiu, E. Romond, W. Hiller, Kyeongmee Park, A. Brown, G. Yothers, S. Anderson, Roy Smith, D. Wickerham, N. Wolmark (2002)
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.Journal of the National Cancer Institute, 94 11
-
PC Roché, VJ Suman, RB Jenkins (2002)
Concordance between local and central laboratory testing in the Breast Intergroup Trial N9831J Natl Cancer Inst, 94
-
M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana‐Hulin, S. Chan, D. Grimes, A. Antón, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, Michael Green, C. Ward, K. Mayne, J. Extra (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 19
-
H. Yaziji, L. Goldstein, T. Barry, R. Werling, H. Hwang, G. Ellis, J. Gralow, R. Livingston, A. Gown (2004)
HER-2 testing in breast cancer using parallel tissue-based methods.JAMA, 291 16
-
E. Ferrari, M. Benhamou, M. Baudouy (2004)
[Cardiotoxicity associated with trastuzumab (herceptin). An undesired effect leads towards a model of cardiac insufficiency].Archives des maladies du coeur et des vaisseaux, 97 4
-
(2003)
Weekly paclitaxel plus trastuzumab shows promising efficacy in advanced breast cancer
- Publisher
- Springer Journals
- Copyright
- Copyright © 2006 by Springer-Verlag
- Subject
- Medicine & Public Health; Biomedicine general; Oncology
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-006-0033-2
- Publisher site
- See Article on Publisher Site
Abstract
This article presents excerpts of the conclusions obtained by a working group applying ANAES (Agence nationale d’accréditation et d’évaluation en santé, France) methodology to the following: Treatment of overexpressed HER2 breast cancers.
Journal
Targeted Oncology – Springer Journals
Published: Oct 12, 2006